Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Rosellini M.; Marchetti A.; Montironi R.; Ardizzoni A.; Massari F., Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials, «EUROPEAN UROLOGY FOCUS», 2021, 1077, pp. 1 - 8 [articolo]
Rizzo A.; Mollica V.; Giunchi F.; Dall'Olio F.G.; Rosellini M.; Marchetti A.; Franceschini T.; Schiavina R.; Brunocilla E.; Fiorentino M.; Ardizzoni A.; Massari F., Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 220, Article number: 153410, pp. 1 - 5 [articolo]
Rizzo, Alessandro; Mollica, Veronica; Giunchi, Francesca; Dall'Olio, Filippo Gustavo; Rosellini, Matteo; Marchetti, Andrea; Franceschini, Tania; Schiavina, Riccardo; Brunocilla, Eugenio; Fiorentino, Michelangelo; Ardizzoni, Andrea; Massari, Francesco, Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience, «PATHOLOGY RESEARCH AND PRACTICE», 2021, 220, pp. 153410 - 153414 [articolo]
Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor, Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase, «VACCINES», 2021, 9, Article number: 19, pp. 1 - 13 [articolo]Open Access
Laprovitera N.; Riefolo M.; Porcellini E.; Durante G.; Garajova I.; Vasuri F.; Aigelsreiter A.; Dandachi N.; Benvenuto G.; Agostinis F.; Sabbioni S.; Berindan Neagoe I.; Romualdi C.; Ardizzoni A.; Trere' D.; Pichler M.; D'Errico A.; Ferracin M., MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary, «MOLECULAR ONCOLOGY», 2021, 15, pp. 2732 - 2751 [articolo]Open Access
Morgensztern D.; Dols M.C.; Ponce Aix S.; Postmus P.E.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Talbot D.; Govindan R.; Ong T.J., nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+), «FRONTIERS IN ONCOLOGY», 2021, 10, Article number: 569715, pp. 1 - 9 [articolo]Open Access
Gelsomino F.; Facchinetti F.; Sisi M.; Zielli T.; Tiseo M.; Ardizzoni A., PD-L1 ≥ 50% lung cancer refractory to PD-1 inhibition: The role of salvage chemo-immunotherapy combination, «IMMUNOTHERAPY», 2021, 13, pp. 363 - 369 [articolo]
Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A., PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors, «CLINICAL LUNG CANCER», 2021, 22, pp. 423 - 431 [articolo]
Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A., PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis, «FUTURE ONCOLOGY», 2021, 17, pp. 4415 - 4424 [articolo]
Minari R.; Bonatti F.; Mazzaschi G.; Dodi A.; Facchinetti F.; Gelsomino F.; Cinquegrani G.; Squadrilli A.; Bordi P.; Buti S.; Bersanelli M.; Leonetti A.; Cosenza A.; Ferri L.; Rapacchi E.; Quaini F.; Ardizzoni A.; Tiseo M., PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors, «TUMORI», 2021, 00(0), pp. 1 - 9 [articolo]
Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Ardizzoni A., PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2021, 160, Article number: 103302, pp. 1 - 5 [articolo]
Pellegrino B.; Cavanna L.; Boggiani D.; Zamagni C.; Frassoldati A.; Schirone A.; Caldara A.; Rocca A.; Gori S.; Piacentini F.; Berardi R.; Brandes A.A.; Foglietta J.; Villa F.; Todeschini R.; Tognetto M.; Naldi N.; Bortesi B.; Montemurro F.; Ardizzoni A.; Boni L.; Musolino A., Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), «ESMO OPEN», 2021, 6, Article number: 100019, pp. 1 - 8 [articolo]Open Access
Brocchi S.; Parmeggiani A.; Gaudiano C.; Balacchi C.; Renzulli M.; Brandi N.; Dall'olio F.G.; Rihawi K.; Ardizzoni A.; Golfieri R., Pneumatosis intestinalis and spontaneous perforation associated with drug toxicity in oncologic patients: A case series, «ACTA GASTRO-ENTEROLOGICA BELGICA», 2021, 84, pp. 497 - 499 [articolo]
Ardizzoni A.; Azevedo S.; Rubio-Viqueira B.; Rodriguez-Abreu D.; Alatorre-Alexander J.; Smit H.J.M.; Yu J.; Syrigos K.; Trunzer K.; Patel H.; Tolson J.; Cardona A.; Perez-Moreno P.D.; Newsom-Davis T., Primary results from TAIL: A global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer, «JOURNAL FOR IMMUNOTHERAPY OF CANCER», 2021, 9, Article number: e001865, pp. 1 - 10 [articolo]Open Access
Mollica, Veronica; Rizzo, Alessandro; Tassinari, Elisa; Giunchi, Francesca; Schiavina, Riccardo; Fiorentino, Michelangelo; Brunocilla, Eugenio; Ardizzoni, Andrea; Massari, Francesco, Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study, «ANTI-CANCER DRUGS», 2021, 32, pp. 74 - 81 [articolo]
